...
首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Treatment of Molecular Relapse by Cessation of Immunosuppression After Hematopoietic Stem Cell Transplantation in Pediatric FLT3-ITD AML Monitored by WT1 Expression in Peripheral Blood
【24h】

Treatment of Molecular Relapse by Cessation of Immunosuppression After Hematopoietic Stem Cell Transplantation in Pediatric FLT3-ITD AML Monitored by WT1 Expression in Peripheral Blood

机译:造血干细胞移植术治疗造血干细胞移植治疗造血干细胞移植治疗外周血血液血液

获取原文
获取原文并翻译 | 示例
           

摘要

Relapse after hematopoietic stem cell transplantation in pediatric acute myeloid leukemia is a fatal event in the majority of cases. Immunotherapy may prevent an impending relapse if instituted at first molecular evidence of disease recurrence. Wilms tumor gene 1 (WT1) is overexpressed in the majority of children and may constitute a useful molecular marker of measurable residual disease applicable for disease monitoring in peripheral blood where the background amplification from healthy hematopoiesis is less prevalent compared with bone marrow. We report the measurable residual disease kinetics from a child with FLT3-internal tandem duplication acute myeloid leukemia where sequential WT1 monitoring in peripheral blood-guided withdrawal of immunosuppression.
机译:在儿科急性髓性白血病中造血干细胞移植后复发是大多数病例的致命事件。 免疫疗法可以防止在第一次疾病复发的分子证据中所制定的暂时复发。 Wilms肿瘤基因1(WT1)在大多数儿童中过表达,可能构成可用于疾病监测的可测量残留疾病的有用分子标记,其与骨髓相比,来自健康血液的背景扩增不太普遍。 我们报告了来自FLT3 - 内部串联复制急性髓性白血病的儿童可衡量的残留疾病动力学,其中在外周血导向免疫抑制中的顺序WT1监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号